688016 心脉医疗
新闻
新帖
单日近2400亿规模,科创板解禁洪峰将至
第一财经 · 06-12
单日近2400亿规模,科创板解禁洪峰将至
高瓴很“忙”:一边澄清传闻 一边收获IPO 投资小秘密也曝光?
科创板日报记者 陈美 · 06-05
高瓴很“忙”:一边澄清传闻 一边收获IPO 投资小秘密也曝光?
微创医疗(00853)发布心脉医疗科技一季度业绩,归母净利润1.23亿元 同比增加21.44%
智通财经 · 04-29
微创医疗(00853)发布心脉医疗科技一季度业绩,归母净利润1.23亿元 同比增加21.44%
心脉医疗(688016.SH)发布一季度业绩,净利润1.23亿元,同比增长21.44%
智通财经 · 04-29
心脉医疗(688016.SH)发布一季度业绩,净利润1.23亿元,同比增长21.44%
心脉医疗:疫情对公司产能有一定限制
财联社 · 04-15
心脉医疗:疫情对公司产能有一定限制
微创电生理科创板上市更进一步:首个国内三维系统具先发优势 然竞品已陆续上市
科创板日报记者 朱洁琰 · 04-14
微创电生理科创板上市更进一步:首个国内三维系统具先发优势 然竞品已陆续上市
上海微创心脉医疗科技(集团)股份有限公司
中国证券报-中证网 · 03-30
上海微创心脉医疗科技(集团)股份有限公司
心脉医疗披露2021年年报 实现营收6.85亿元
资本邦 · 03-30
心脉医疗披露2021年年报 实现营收6.85亿元
微创医疗(00853)发布心脉医疗科技2021年业绩 心脉医疗科技股东应占利润3.16亿元 同比增长47.17%
智通财经 · 03-29
微创医疗(00853)发布心脉医疗科技2021年业绩 心脉医疗科技股东应占利润3.16亿元 同比增长47.17%
心脉医疗(688016.SH)发布2021年业绩,净利润3.16亿元,增长47.17%,每10股派21元
智通财经网 · 03-29
心脉医疗(688016.SH)发布2021年业绩,净利润3.16亿元,增长47.17%,每10股派21元
心脉医疗:前2月营收同比增长35%左右
财联社 · 03-16
心脉医疗:前2月营收同比增长35%左右
心脉医疗业绩快报:2021年净利同比增长47%
财联社 · 02-24
心脉医疗业绩快报:2021年净利同比增长47%
心脉医疗(688016.SH)业绩快报:2021年归母净利同比增47.3%至3.16亿元
智通财经 · 02-24
心脉医疗(688016.SH)业绩快报:2021年归母净利同比增47.3%至3.16亿元
未上市即坐稳“市值老大”位置,微创系再度拆分上市
华尔街见闻 · 01-12
未上市即坐稳“市值老大”位置,微创系再度拆分上市
心脉医疗:01月06日高管本人或关联人鹿洪杰增持股份200股
资本邦 · 01-12
心脉医疗:01月06日高管本人或关联人鹿洪杰增持股份200股
心脉医疗(688016.SH):直管型胸主动脉覆膜支架系统获得医疗器械注册证
智通财经 · 01-11
心脉医疗(688016.SH):直管型胸主动脉覆膜支架系统获得医疗器械注册证
心脉医疗(688016.SH)获得“分支型术中支架系统”医疗器械注册证
智通财经 · 2021-12-17
心脉医疗(688016.SH)获得“分支型术中支架系统”医疗器械注册证
心脉医疗(688016.SH)获“外周高压球囊扩张导管产品”医疗器械注册证
智通财经 · 2021-11-15
心脉医疗(688016.SH)获“外周高压球囊扩张导管产品”医疗器械注册证
微创医疗(00853.HK)附属心脉医疗首三季纯利增54%
AAFN · 2021-10-29
微创医疗(00853.HK)附属心脉医疗首三季纯利增54%
微创医疗(00853):前三季度归属于心脉医疗科技股权持有人的净利润约2.5亿元 同比增长53.93%
智通财经 · 2021-10-28
微创医疗(00853):前三季度归属于心脉医疗科技股权持有人的净利润约2.5亿元 同比增长53.93%
加载更多
{"market":"A","stockBase":{"symbol":"688016","market":"SH","secType":"STK","nameCN":"心脉医疗","latestPrice":198.08,"timestamp":1656054238000,"preClose":198.57,"halted":0,"volume":746445,"delay":0,"change":-0.49,"changeRate":-0.0025,"floatShares":38625200,"shares":71978100,"eps":4.6911,"pbRate":8.81,"amount":149000000,"amplitude":0.0481,"prevYearClose":248.74,"fiveDayClose":207.58,"twentyDayClose":165.99},"adData":{"groupTypeList":[],"userSplitList":[]},"requestUrl":"/m/hq/s/688016","defaultTab":"news","newsList":[{"id":"2242952518","title":"单日近2400亿规模,科创板解禁洪峰将至","url":"https://stock-news.laohu8.com/highlight/detail?id=2242952518","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2242952518?lang=zh_CN&edition=full","pubTime":"2022-06-12 21:07","pubTimestamp":1655039220,"startTime":"0","endTime":"0","summary":" 科创板即将迎来开市三周年。根据科创板规定,控股股东和实际控制人自股票上市之日起锁定期限为三年,这意味着科创板解禁压力最高峰将至。 数据显示,2022年科创板总解禁规模约10968亿元,其中“大非”——持有限售解禁股占公司总股本的5%以上股东的解禁规模合计5400亿元,其余均为“小非”解禁。 7月份科创板的解禁规模为2703亿元,为年内单月解禁最高。而单日近2400亿元的解禁洪峰,对大盘整体的潜在冲击不容小窥。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2022-06-12/doc-imizmscu6453913.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/roll/2022-06-12/doc-imizmscu6453913.shtml?finpagefr=p_115","is_publish_highlight":false},{"id":"2241779025","title":"高瓴很“忙”:一边澄清传闻 一边收获IPO 投资小秘密也曝光?","url":"https://stock-news.laohu8.com/highlight/detail?id=2241779025","media":"科创板日报记者 陈美","top":-1,"share":"https://www.laohu8.com/m/news/2241779025?lang=zh_CN&edition=full","pubTime":"2022-06-05 08:22","pubTimestamp":1654388520,"startTime":"0","endTime":"0","summary":"拆分上市,已成为高瓴的一张王牌。除微创系以外,记者发现,与高瓴合作的公司中,大族激光、丽珠集团、协鑫科技、凯莱英、金斯瑞等多家公司均有拆分上市,或者二次上市的计划。","market":"hk","thumbnail":"https://img.cls.cn/images/20220605/tQ4z20B27T.jpg","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20220605/tQ4z20B27T.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.chinastarmarket.cn/detail/1033737","is_publish_highlight":false},{"id":"2231236773","title":"微创医疗(00853)发布心脉医疗科技一季度业绩,归母净利润1.23亿元 同比增加21.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2231236773","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2231236773?lang=zh_CN&edition=full","pubTime":"2022-04-29 21:57","pubTimestamp":1651240655,"startTime":"0","endTime":"0","summary":"智通财经APP讯,微创医疗(00853)发布公告,该公司附属心脉医疗科技截至2022年3月31日止3个月取得收入人民币2.58亿元,同比增加30.59%;归属于心脉医疗科技股权持有人的净利润人民币1.23亿元,同比增加21.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/717496.html","is_publish_highlight":false},{"id":"2231728184","title":"心脉医疗(688016.SH)发布一季度业绩,净利润1.23亿元,同比增长21.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2231728184","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2231728184?lang=zh_CN&edition=full","pubTime":"2022-04-29 19:38","pubTimestamp":1651232322,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗(688016.SH)发布2022年第一季度报告,营业收入2.58亿元,同比增长30.59%;归属于上市公司股东的净利润1.23亿元,同比增长21.44%;归属于上市公司股东的扣除非经常性损益的净利润1.18亿元,同比增长19.66%;基本每股收益1.72元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/716984.html","is_publish_highlight":false},{"id":"2227086226","title":"心脉医疗:疫情对公司产能有一定限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2227086226","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2227086226?lang=zh_CN&edition=full","pubTime":"2022-04-15 12:37","pubTimestamp":1649997436,"startTime":"0","endTime":"0","summary":"财联社4月15日电,财联社记者从心脉医疗2021年度业绩会上获悉,公司所在地上海浦东目前仍处在封闭管理状态,因此对公司生产经营有一定影响,其中,部分生产工人仍处于居家隔离管控中,公司产能受到一定限制。在此封控期间,为保障不停工停产,公司目前仍安排部分生产人员24小时驻守生产车间,封闭管控原因导致研发人员目前居家办公,且国内特别是上海地区的物流发货效率降低,对公司前、后端业务均形成一定影响,公司正积极采取一切可能的措施以降低本次疫情管控对公司生产经营产生的负面影响。(财联社记者王俊仙)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.cls.cn/detail/987343","is_publish_highlight":false},{"id":"2227462556","title":"微创电生理科创板上市更进一步:首个国内三维系统具先发优势 然竞品已陆续上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2227462556","media":"科创板日报记者 朱洁琰","top":-1,"share":"https://www.laohu8.com/m/news/2227462556?lang=zh_CN&edition=full","pubTime":"2022-04-14 09:11","pubTimestamp":1649898688,"startTime":"0","endTime":"0","summary":"在心脏电生理领域,公司是全球少数同时完成心脏电生理设备与耗材完整布局的厂商之一,亦是首个能够提供三维心脏电生理设备与耗材完整解决方案的本土厂商。","market":"sh","thumbnail":"https://img.cls.cn/images/20220414/53u3bE1qkj.jpg@!thumb_flash","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20220414/53u3bE1qkj.jpg@!thumb_flash"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://m.cls.cn/depth/985851","is_publish_highlight":false},{"id":"2223369870","title":"上海微创心脉医疗科技(集团)股份有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2223369870","media":"中国证券报-中证网","top":-1,"share":"https://www.laohu8.com/m/news/2223369870?lang=zh_CN&edition=full","pubTime":"2022-03-30 05:44","pubTimestamp":1648590256,"startTime":"0","endTime":"0","summary":"公司代码:688016公司简称:心脉医疗上海微创心脉医疗科技(集团)股份有限公司第一节重要提示1本年度报告摘要来自年度报告全文,为全面了解本公司的经营成果、财务状况及未来发展规划,投资者应当到www.sse.com.cn网站仔细阅读年度报告全文。本次2021年度利润分配方案尚需提交公司2021年年度股东大会审议通过。报告期内,公司主营业务未发生重大变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-03-30/doc-imcwipii1326495.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-03-30/doc-imcwipii1326495.shtml","is_publish_highlight":false},{"id":"2223257874","title":"心脉医疗披露2021年年报 实现营收6.85亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2223257874","media":"资本邦","top":-1,"share":"https://www.laohu8.com/m/news/2223257874?lang=zh_CN&edition=full","pubTime":"2022-03-30 00:00","pubTimestamp":1648569600,"startTime":"0","endTime":"0","summary":"心脉医疗发布2021年年报,实现营业收入6.85亿元,同比增长45.59%,净利润3.16亿元,同比增长47.17%。","market":"hk","thumbnail":"https://www.chinaipo.com/data/upload/2021/0628/17/60d99a27213e2_300_200.jpg","type":0,"news_type":0,"thumbnails":["https://www.chinaipo.com/data/upload/2021/0628/17/60d99a27213e2_300_200.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.chinaipo.com/news/622553.html","is_publish_highlight":false},{"id":"2223799825","title":"微创医疗(00853)发布心脉医疗科技2021年业绩 心脉医疗科技股东应占利润3.16亿元 同比增长47.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2223799825","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2223799825?lang=zh_CN&edition=full","pubTime":"2022-03-29 21:40","pubTimestamp":1648561206,"startTime":"0","endTime":"0","summary":"智通财经APP讯,微创医疗(00853)发布心脉医疗科技2021年业绩,心脉医疗科技收入6.84亿元人民币(单位下同),同比增长45.59%;归属于心脉医疗科技股权持有人的净利润3.16亿元,同比增长47.17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/691523.html","is_publish_highlight":false},{"id":"2223412148","title":"心脉医疗(688016.SH)发布2021年业绩,净利润3.16亿元,增长47.17%,每10股派21元","url":"https://stock-news.laohu8.com/highlight/detail?id=2223412148","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2223412148?lang=zh_CN&edition=full","pubTime":"2022-03-29 17:30","pubTimestamp":1648546257,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗 发布2021年业绩公告,报告期内公司实现营业收入6.85亿元,相较上年同期增长45.59%;营业利润3.63亿元,相较上年同期增长45.15%;归属于上市公司股东的净利润3.16亿元,相较上年同期增长47.17%;归属于上市公司股东的扣除非经常性损益的净利润2.88亿元,相较上年同期增长51.08%。综上所述,虽然受到新冠肺炎疫情反复的一定影响,但公司整体经营态势仍旧表现良好,报告期内销售收入及净利润仍旧保持着良好的持续增长态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/691053.html","is_publish_highlight":false},{"id":"2219579157","title":"心脉医疗:前2月营收同比增长35%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2219579157","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2219579157?lang=zh_CN&edition=full","pubTime":"2022-03-16 16:36","pubTimestamp":1647419771,"startTime":"0","endTime":"0","summary":"【心脉医疗:前2月营收同比增长35%左右】《科创板日报》16日讯,心脉医疗公告,1至2月,公司实现营业收入1.87亿元人民币左右,较去年同期同比增长35%左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.cls.cn/detail/960306","is_publish_highlight":false},{"id":"2213946060","title":"心脉医疗业绩快报:2021年净利同比增长47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2213946060","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2213946060?lang=zh_CN&edition=full","pubTime":"2022-02-24 17:36","pubTimestamp":1645695397,"startTime":"0","endTime":"0","summary":"财联社2月24日电,心脉医疗公告,2021年实现营业总收入6.85亿元,较上年同期增长45.59%;实现归属于上市公司股东的净利润3.16亿元,较上年同期增长47.3%。基本每股收益4.39元。公司的创新性产品包括Castor分支型主动脉覆膜支架及输送系统、Minos腹主动脉覆膜支架及输送系统、ReewarmPTX药物球囊扩张导管等新产品在报告期内仍持续获得快速增长;海外业务收入亦获得快速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.cls.cn/detail/942501","is_publish_highlight":false},{"id":"2213091946","title":"心脉医疗(688016.SH)业绩快报:2021年归母净利同比增47.3%至3.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2213091946","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2213091946?lang=zh_CN&edition=full","pubTime":"2022-02-24 17:32","pubTimestamp":1645695172,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗 披露2021年度业绩快报,该公司2021年度实现营业总收入6.85亿元,同比增长45.59%。归属于上市公司股东的净利润3.16亿元,同比增长47.30%。归属于母公司所有者的扣除非经常性损益的净利润2.89亿元,同比增长51.22%。基本每股收益为4.39元/股。同时随着公司创新性产品在国际市场的开拓力度不断加大,海外业务收入亦获得快速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/664134.html","is_publish_highlight":false},{"id":"2202731834","title":"未上市即坐稳“市值老大”位置,微创系再度拆分上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2202731834","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2202731834?lang=zh_CN&edition=full","pubTime":"2022-01-12 16:11","pubTimestamp":1641975080,"startTime":"0","endTime":"0","summary":"","market":"sh","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","source_url":"https://wallstreetcn.com/articles/3649120","is_publish_highlight":true},{"id":"2202665735","title":"心脉医疗:01月06日高管本人或关联人鹿洪杰增持股份200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2202665735","media":"资本邦","top":-1,"share":"https://www.laohu8.com/m/news/2202665735?lang=zh_CN&edition=full","pubTime":"2022-01-12 00:00","pubTimestamp":1641916800,"startTime":"0","endTime":"0","summary":"心脉医疗称:2022年01月06日高管本人或关联人鹿洪杰增持股份200股。","market":"hk","thumbnail":"https://www.chinaipo.com/data/upload/2021/0628/17/60d99aba967df_300_200.jpg","type":0,"news_type":0,"thumbnails":["https://www.chinaipo.com/data/upload/2021/0628/17/60d99aba967df_300_200.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.chinaipo.com/news/409428.html","is_publish_highlight":false},{"id":"2202202359","title":"心脉医疗(688016.SH):直管型胸主动脉覆膜支架系统获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2202202359","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2202202359?lang=zh_CN&edition=full","pubTime":"2022-01-11 16:58","pubTimestamp":1641891539,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗(688016.SH)发布公告,近日,该公司获得国家药品监督管理局颁发的关于直管型胸主动脉覆膜支架系统的医疗器械注册证,上述产品医疗器械注册证的获得,进一步丰富了公司现有产品种类,扩充公司在主动脉领域的产品线布局,将进一步推动公司在主动脉领域的市场拓展,不断满足市场需求,从而进一步增强公司的核心竞争力。","market":"us","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/638901.html","is_publish_highlight":false},{"id":"2192218429","title":"心脉医疗(688016.SH)获得“分支型术中支架系统”医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2192218429","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2192218429?lang=zh_CN&edition=full","pubTime":"2021-12-17 15:46","pubTimestamp":1639727192,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗(688016.SH)发布公告,近日,公司获得国家药品监督管理局颁发的关于分支型术中支架产品的医疗器械注册证,该产品适用于Stanford \nA型和常规介入无法治疗的复杂Stanford B型主动脉夹层的手术治疗。上述产品医疗器械注册证的获得,进一步丰富了公司现有产品种类,扩充公司在主动脉外科手术领域的产品线布局,将进一步推动公司在主动脉外科手术领域的市场拓展,不断满足市场需求,从而进一步增强公司的核心竞争力。","market":"hk","thumbnail":"https://static.tigerbbs.com/060ad0458b052bd2b9e3c7afae3df1f5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/060ad0458b052bd2b9e3c7afae3df1f5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/624084.html","is_publish_highlight":false},{"id":"2183025194","title":"心脉医疗(688016.SH)获“外周高压球囊扩张导管产品”医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2183025194","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2183025194?lang=zh_CN&edition=full","pubTime":"2021-11-15 16:27","pubTimestamp":1636964879,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心脉医疗(688016.SH)公告,近日,公司获得国家药品监督管理局颁发的关于外周高压球囊扩张导管产品的医疗器械注册证,将扩充公司在外周领域的产品线布局。公告显示,该产品适用于外周血管系统(包括髂动脉、股动脉、腘动脉、胫动脉、腓动脉、锁骨下动脉和肾动脉)的经皮腔内血管成形术(PTA),并适用于治疗自体或人造透析用动静脉瘘的堵塞病变。同时适用于外周血管系统中的球囊扩张支架或自扩张支架的后扩张。","market":"us","thumbnail":"https://static.tigerbbs.com/060ad0458b052bd2b9e3c7afae3df1f5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/060ad0458b052bd2b9e3c7afae3df1f5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/601885.html","is_publish_highlight":false},{"id":"2179922112","title":"微创医疗(00853.HK)附属心脉医疗首三季纯利增54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2179922112","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2179922112?lang=zh_CN&edition=full","pubTime":"2021-10-29 09:13","pubTimestamp":1635470028,"startTime":"0","endTime":"0","summary":"微创医疗 公布,持股约46.34%之心脉医疗科技(688016.SH)至今年9月底止首三季业绩,收入为5.1亿元人民币(下同),按年增55.45%,纯利为2.5亿元,增53.93%。(ic/s)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1138577&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2178526998","title":"微创医疗(00853):前三季度归属于心脉医疗科技股权持有人的净利润约2.5亿元 同比增长53.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2178526998","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2178526998?lang=zh_CN&edition=full","pubTime":"2021-10-28 20:10","pubTimestamp":1635423006,"startTime":"0","endTime":"0","summary":"智通财经APP讯,微创医疗(00853)公布心脉医疗科技2021年前9个月业绩,收入约5.1亿元,同比增长55.45%;归属于心脉医疗科技股权持有人的净利润约2.5亿元,同比增长53.93%。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/586973.html","is_publish_highlight":false}],"isWeiXinMini":false,"pagemeta":{"title":"心脉医疗(688016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供心脉医疗(688016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"心脉医疗,688016,心脉医疗股票,心脉医疗股票老虎,心脉医疗股票老虎国际,心脉医疗行情,心脉医疗股票行情,心脉医疗股价,心脉医疗股市,心脉医疗股票价格,心脉医疗股票交易,心脉医疗股票购买,心脉医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情"}}
null